Objectives-To explore the risk factors on contrast agent venous intravasation during transvaginal 4-dimensional hysterosalpingo-contrast sonography (TVS 4D-HyCoSy).
Introduction
F allopian obstruction and pelvic adhesion represent the main causes of female infertility, accounting for about 30% to 35% of female infertility. 1 Primary infertility is a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Secondary infertility refers to women who have had a pregnancy before and have not been pregnant for 1 year. 2 Compared with laparoscopy, transvaginal 4-dimensional hysterosalpingo-contrast sonography (TVS 4D-HyCoSy) is a novel imaging technique for assessment of fallopian tube obstruction with satisfactory sensitivity and specificity. 3, 4 It is becoming the preferred screening means for fallopian tube obstruction as an alternative for traditional x-ray-based hysterosalpingography (HSG), due to its cost efficiency, clear images, and nonionizing radiation. 5 However, the sonographic contrast agent, the size of which is half of a red blood cell, is prone to diffusing into blood vessels or lymphatic vessels, which is called intravasation. 6, 7 A recent case report showed that venous intravasation can occur during HyCoSy, causing false-negative results due to contrast media in the venous plexus. 8 Although contrast media venous intravasation is unlikely to induce embolism, which can be seen in lipiodol-based HSG, it may increase the risk of the side effects such as pain and infection. 9 It is reported that the incidence of venous intravasation during HSG is 11.27%. 10 However, there is limited study of the symptom in TVS 4D-HyCoSy. Recent investigations reported an incidence of 26.3% to 41.3% for contrast agent intravasation during 4D-HyCoSy without distinguishing myometrial intravasation and venous intravasation. [11] [12] [13] Two hundred seventy-six patients were included in this study, and venous intravasation was found in 36 cases (13.04%). Endometrial thickness and days after menstruation are identified as risk factors on venous intravasation of contrast agent.
Materials and Methods

Study Participants
In this prospective observational study, 276 patients at a fertility clinic, examined by TVS 4D-HyCoSy from September 2016 to December 2016, were included in our study. The study was approved by the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University. All of the participants were free of contraindications for HyCoSy and signed informed consents. Contraindications included vaginal bleeding, acute sexually transmitted disease, and acute or subacute inflammation in the reproductive system. The cleanliness of vaginal secretions in the participants was of the first or second degree. The HyCoSy was performed 3 to 9 days after menstruation, and the intrauterine intervention history and the examination date were recorded. 14 
Instruments and Methods
All the examinations were performed using the Voluson E8 Expert (GE Healthcare, Milwaukee, WI) ultrasound machine with a transvaginal 3-dimensional probe and dedicated coded contrast-imaging software. The parameters were set as follows: mechanical index, 0.12 to 0.18; frequency, 5.0 to 9.0 MHz; scan angle: 08 to 1798. Transvaginal 4-dimensional hysterosalpingo-contrast sonography was performed using the SonoVue contrast agent (Bracco International BV, Amsterdam, the Netherlands). Briefly, the contrast agent was prepared by adding 5 mL of 0.9% saline solution to 59 mg of SonoVue freeze-dried powder with a sufficient suspension; then 2.0 mL of the SonoVue suspension was aspirated and diluted to 20 mL with a 0.9% saline solution for use.
Each examination was performed by 2 experienced physicians. A prescan using 2-dimensional transvaginal sonography was conducted before 4D-HyCoSy to check the condition of the uterus, fallopian tube, and pelvic cavity. The thickness of the endometrium at 5 to 10 mm to the bottom of the uterus was measured during the 2-dimensional examination and classified into 3 grades: 3.5 mm or less, 3.6 to 5.9 mm, and 6.0 mm or greater. 15 Each patient was put in the lithotomic position with the cervix exposed and fixed after routine disinfection and draping. A number 12 dual-lumen catheter was placed into the uterine cavity, and 1.0 to 2.0 mL of normal saline was injected into the external lumen. An appropriate initial plane for 3-dimensional imaging was selected by positioning the vaginal probe at the level of the sectional plane of the uterus, with slight adjustment to allow visualization of bilateral uterine horns and surrounding tissues. The 4D-HyCoSy was activated while keeping the probe at the same position with the region of interest as wide as possible. The contrast agent within the uterine cavity and fallopian tube, as well as its overflow from the tubal umbrella, was observed while an assistant injected the contrast agent into the uterine cavity via catheter at a rate of 0.5 mL/s. The occurrence of contrast agent intravasation into the uterine myometrium and venous plexus was recorded in the meantime. The dynamic imaging data were stored by pressing the P2 button, while the static images were stored by pressing the P1 button after switching back to the 3-dimensional mode. The diffusion of the contrast agent surrounding the ovaries and within the pelvic cavity was observed and saved under the coded contrast imaging mode. The dynamic enhanced volume images were reviewed by frame after the imaging procedure and analyzed.
Criteria for Contrast Agent Venous Intravasation 12
Contrast agent intravasation during 4D-HyCoSy may occur in the uterine myometrium or venous plexus, or both. Intravasation in the uterine myometrium can be observed as spotlike high signal enhancement from the contrast agent in a limited region, or cloudlike diffused signal enhancement within the myometrium on 4D-HyCoSy images ( Figure 1 ). As for the venous plexus, there is cord or netlike signal enhancement around the uterus extending to surrounding tissue without specific direction ( Figure 2 ). All the venous plexus intravasation was considered contrast agent venous intravasation.
Criteria for Fallopian Tube Patency Evaluated by 4D-HyCoSy 16
Fallopian Tube Patency The entire fallopian tube develops completely and naturally. There is sheet-or ejecting-like overflow of the contrast agent in the fallopian fimbria extremity. The circle-like wrapping of the contrast medium can be observed around the ovary. The contrast agent diffuses evenly in the pelvic cavity.
Fallopian Tube Obstruction
Apparent resistance exists during injection of the contrast agent. The distal segment of fallopian tube is obviously enlarged and distorted. No overflow of the contrast medium from fallopian fimbriae can be seen. No or little contrast medium can be seen around the ovary. No diffusion of contrast medium can be seen in the lateral pelvic cavity.
Statistical Analyses
The incidence of contrast agent venous intravasation was evaluated on the basis of the intrauterine intervention history, endometrial thickness, fallopian tubal patency (patency, unilateral obstruction, and bilateral obstruction) and examination date after menstrual period (3-4, 5-7, and 8-9 days). 14, 15 The Pearson v 2 test was used to compare the difference among groups.
A multivariate logistic regression model was fitted with contrast venous intravasation as the response and endometrial thickness, days after the menstrual period, fallopian tubal patency, and intrauterine intervention history as independent variables. All of the analyses were conducted with SPSS version 18.0 software (IBM Corporation, Armonk, NY).
Results
The age of the participants ranged from 23 to 44 years, with a mean age 6 SD 32.4 6 2.1 years. Eight patients (6.45%) had a diagnosis of primary infertility, and 25 patients (16.45%) had a diagnosis of secondary infertility. The infertility history of these 33 patients ranged from 1 to 14 years, with a mean of 4.3 6 2.2 years. Contrast agent venous intravasation occurred in 36 of 276 patients, with an overall incidence of 13.04%. Table 1 lists the number of cases and incidence of contrast agent venous intravasation by endometrial thickness, examination date after the menstrual period ended, intrauterine intervention history, and tubal obstruction. The Pearson v 2 test showed a statistically significant association between contrast agent venous intravasation and endometrial thickness (P 5 .009) and days of the examination date after the menstrual period (P 5 .003) but no association with the intrauterine intervention history (P 5 .443). Although there was an observable difference in the incidence of intravasation among patients with/without tubal obstruction, the statistical significance was marginal (P 5 .089).
The incidence of intravasation was 50.0% (2 of 4) of patients with the smallest endometrial thickness (3.5 mm), and the rate was 15.24% (28 of 179) when endometrial thickness was 3.5 to 5.9 mm, whereas the lowest rate remained 6.45% (6 of 93) when endometrial thickness was no less than 6.0 mm (6.0 mm). For the examination date after menstruation, the lowest incidence appeared in the group of 5 to 7 days after menstruation (9.25%), lower than those in 3 to 4 days (14.08%) and 8 to 9 days (31.25%). As expected, the incidence of intravasation was the lowest among patients without tubal obstruction (10.75%). The intravasation rate of patients with unilateral tubal obstruction (23.53%) was slightly higher than those with bilateral obstruction (17.86%; Table 1 ).
The analysis results from the multivariate logistic regression model conformed to the findings by univariate analyses (Table 2 ). There was a significant association between contrast agent venous intravasation and endometrial thickness (P < .005) and the examination date after menstruation (P < .010), respectively. The endometrial thickness was reported as a protection factor. No association was reported between the intrauterine intervention history (P 5 .694) and tubal patency (P 5 .200) and contrast agent venous intravasation, respectively.
Discussion
Transvaginal 4-dimensional hysterosalpingo-contrast sonography is a low-cost and noninvasive approach to assessment of tubal patency. The accuracy of TVS 4D-HyCoSy is well recognized by clinicians, which makes it a common imaging technique for infertility screening and indirect assessment of fallopian tubal function in current clinical practice. 3, [17] [18] [19] [20] The contrast agentenhanced imaging approach is able to track the flow of the contrast agent injected into the uterine cavity, taking advantage of signal enhancement produced by differential acoustic reflection across the aero-aqueous interface of the microbubble, providing real-time dynamic visualization of fallopian tubal morphologic characteristics. However, diffusion of the contrast agent into the uterine myometrium and/or venous vessels may lead to artifacts that compromise the visualization of tubal shape and patency. Substantial contrast agent venous intravasation may mask the border of the uterine cavity and tubal lumen and make the images inconclusive. Our study shows that the venous intravasation of contrast agent happens commonly (13.04%) during TVS 4D-HyCoSy. The incidence is slightly higher than that for HSG with iodized oil 10 but lower than what was reported by other studies (26.3%-41.3%).
11-13
The extent of contrast agent intravasation from the uterine cavity into the uterine myometrium and venous plexus depends on the integrity of the uterine inner surface, the amount of contrast agent injected into uterine cavity, and the injection pressure.
12,21 It Wang et al-Contrast Agent Venous Intravasation in 4D-HyCoSy was found in this study that the endometrial thickness and examination date after the menstrual cycle were associated with the incidence of contrast agent venous intravasation (P < .05). The incidence of venous intravasation is contrarily associated with endometrial thickness. The venous intravasation rate was 50% (2 of 4) in patients with endometrial thickness less than 3.5 mm but dropped dramatically to 6.45% (6 of 93) in patients whose endometrial thickness was no less than 6.0 mm. The result suggests that the endometrium helps prevent the contrast agent from penetrating into the uterine myometrium and venous plexus, which is consistent with the previous study. 11 With respect to 2 venous intravasation cases with a thinner endometrium (3.5 mm), the second TVS 4D-HyCoSy conducted 3 days later revealed a slight increase in endometrial thickness and disappearance or reduction of contrast agent intravasation. The venous intravasation disappeared in 1 patient and turned into mild intravasation in another patient without an obvious influence on imaging (Figure 3) . These results from within-subject repeated examinations provide further evidence for an association between endometrial thickness and contrast agent intravasation.
The incidence of venous intravasation reached its peak, at 31.25%, in patients undergoing TVS 4D-HyCoSy at 8 to 9 days after their menstrual cycle, whereas the lowest rate (9.25%) was observed in patients at 5 to 7 days after their menstrual cycle. The time distribution of intravasation is consistent with the recommended time window for routine clinical intrauterine intervention, at 3 to 7 days after the menstrual cycle. Higher venous intravasation rates, at 8 to 9 days after the menstrual cycle, may associate with higher estrogen levels and gradual expansion of endometrial microvessels during the endometrial proliferative phase. However, the thickening endometrium near the interstitial portion of the fallopian tube may lead to pseudo-blocking of the proximal tube, which might increase resistance to contrast agent injection. The higher injection pressure to overcome the resistance may be associated with contrast agent intravasation as well.
The incidence of contrast agent venous intravasation in patients with fallopian tubal obstruction (bilateral, 17.86%; unilateral, 23.53%) tends to be higher than that in patients without tubal obstruction (10.75%), although the statistical significance was marginal (P 5 .089). The injection pressure of the contrast agent will increase in the case of tubal obstruction due to higher resistance to contrast agent flow. The higher injection pressure may force the contrast agent to penetrate through the interstitial portion of the endometrium and enter into the uterine myometrium and venous vessels, inducing venous intravasation. Interestingly, the incidence of intravasation in patients with bilateral tubal obstruction, for whom the pathway of contrast agent flow is blocked completely, is lower than that in patients with unilateral tubal obstruction. It is possible that the operator may inject more contrast agent with higher pressure into the uterine cavity to confirm unilateral tubal obstruction, which is more difficult to determine than bilateral obstruction. Therefore, the higher pressure and amount of contrast agent lead to more severe contrast agent intravasation in patients with unilateral tubal obstruction. This study demonstrated that the incidence of contrast agent venous intravasation during TVS 4D-HyCoSy is the lowest among patients whose endometrial thickness is around 6.0 mm and who undergo examinations at 5 to 7 days after their menstrual cycle. Avoiding contrast agent intravasation is helpful to reduce the false-positive rate during diagnosis of fallopian tubal patency, as well as repeated examinations, due to technical inadequacy caused by intravasation. Therefore, the best time window for TVS 4D-HyCoSy should be planned according to the menstrual cycle. For patients with a menstrual cycle length greater than 30 to 35 days, the best time to conduct TVS 4D-HyCoSy should be at 5 to 7 days after the menstrual cycle. For patients with a menstrual cycle length less than 28 to 30 days, the best examination time should be at 3 to 5 days after the menstrual cycle. An examination conducted earlier may increase the risk of venous intravasation because of the exposure of micro blood vessels to the contrast agent due to incomplete recovery of the endometrium. On the other hand, an examination conducted too late may also increase the venous intravasation risk because of higher microvessel fragility due to gradual expansion of endometrial microvessels during the endometrial proliferative phase. 15 In conclusion, the incidence of contrast agent venous intravasation in TVS 4D-HyCoSy is associated with endometrial thickness and the examination date after the menstrual cycle. Planning the examination according to endometrial thickness and the menstrual cycle will be helpful to reduce the incidence of intravasation during TVS 4D-HyCoSy and avoid false-positive results due to a thickened endometrium, thereby improving diagnostic accuracy.
